ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

NIH, FDA to tighten, review consulting rules as Congressional inquiry continues.

May 21, 2004

Cancer Advocacy: March On Washington Scheduled For September 1998

October 31, 1997

New Grants Awarded In Tobacco Research

February 17, 1978

HHS Awards $85 Million For Research to Eliminate Health Disparities

November 15, 2002

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Komen Deal With KFC Yields Buckets Of Discord

April 23, 2010